Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis

• Published in: Frontiers in oncology Vol. 11; p. 641878
• Main Authors: Chen, Wenlin, Wang, Yuekun, Zhao, Binghao, Liu, Penghao, Liu, Lei, Wang, Yu, Ma, Wenbin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29-03-2021
• Subjects: Bayesian network meta-analysis; bevacizumab; combination therapy; Oncology; recurrent glioblastoma; systematic review; recurrent glioblastoma; bevacizumab; combination therapy; systematic review; Bayesian network meta-analysis
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.641878

The optimal treatment of recurrent glioblastoma (GBM) remains controversial. Therefore, our study aimed to compare and rank active therapies in recurrent GBM. We performed a systematic review and a Bayesian network meta-analysis. We obtained a treatment hierarchy using the surface under the cumulative ranking curve and mean ranks. A cluster analysis was conducted to aggregate the separated results of three outcomes. The protocol was registered in PROSPERO (CRD42019146794). A total of 1,667 citations were identified, and 15 eligible articles with 17 treatments remained in the final network meta-analysis. Pairwise comparison showed no significant difference on the 6-month progression-free survival (6-m PFS) rate, objective response rate (ORR), and overall survival (OS). Among the reports, cediranib plus lomustine (CCNU) corresponded to the highest rates of grade 3-4 adverse events. Ranking and cluster analysis indicated that bevacizumab (BEV) plus CCNU and regorafenib had a higher efficacy on the ORR, 6-m PFS rate and OS, and that BEV monotherapy or BEV combined with active drug therapies was advantageous for the ORR and 6-m PFS rate. Additionally, tumor treatment fields (TTF) plus BEV showed a relatively higher SUCRA value in OS. According to ranking and cluster analysis, BEV plus CCNU and regorafenib are the primary recommendations for treatment. BEV monotherapy alone or combined with active drug therapies are recommended in patients with severe neurological symptoms. Advanced therapy, such as TTF and immunotherapy, remain to be investigated in future studies.